Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,365 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04699461 | Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma(LOTIS-6) | terminated | Phase 2 | 6 | ADC Therapeutics S.A.INDUSTRY | 10 | Oct 23, 2023 | clinicaltrials |
| NCT03330405 | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 223 | PfizerINDUSTRY | 9 | Oct 13, 2023 |
| clinicaltrials |
| NCT04891185 | Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer(VIPIDO) | terminated | Phase 2 | 14 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT00804856 | Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia | completed | Phase 2 | 180 | Boehringer IngelheimINDUSTRY | 7 | Oct 3, 2023 | clinicaltrials |
| NCT02391545 | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) | terminated | Phase 1 / Phase 2 | 55 | SecuraBioINDUSTRY | 6 | Sep 28, 2023 | clinicaltrials |
| NCT04059224 | TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma(TraMel-WT) | completed | Phase 2 | 45 | Universitair Ziekenhuis BrusselOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT03565991 | Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors | terminated | Phase 2 | 202 | PfizerINDUSTRY | 9 | Sep 25, 2023 | clinicaltrials |
| NCT05370235 | A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V | unknown | Phase 2 | 6 | Clinuvel Europe LimitedINDUSTRY | 2 | Sep 21, 2023 | clinicaltrials |
| NCT04145700 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma | terminated | Phase 1 / Phase 2 | 23 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 13, 2023 | clinicaltrials |
| NCT04099888 | PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer(RELEASE) | terminated | Phase 2 | 41 | PCI Biotech ASINDUSTRY | 14 | Sep 11, 2023 | clinicaltrials |
| NCT01882803 | A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma(DYNAMO) | completed | Phase 2 | 129 | SecuraBioINDUSTRY | 12 | Sep 7, 2023 | clinicaltrials |
| NCT01558427 | Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer | completed | Phase 2 | 62 | University Hospital, GhentOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT02028364 | Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women(PEARL) | completed | Phase 2 | 55 | Jules Bordet InstituteOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT02034110 | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | completed | Phase 2 | 206 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 21, 2023 | clinicaltrials |
| NCT03840915 | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 70 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Aug 21, 2023 | clinicaltrials |
| NCT02614794 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer(HER2CLIMB) | completed | Phase 2 | 612 | Seagen Inc.INDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT01813539 | A Study of ARGX-110 in Participants With Advanced Malignancies | completed | Phase 1 / Phase 2 | 99 | OncoVerity, Inc.INDUSTRY | 2 | Aug 9, 2023 | clinicaltrials |
| NCT04495179 | A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.(AARDVARC) | completed | Phase 2 | 30 | AstraZenecaINDUSTRY | 5 | Aug 9, 2023 | clinicaltrials |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy | terminated | Phase 1 / Phase 2 | 8 | GenmabINDUSTRY | 3 | Aug 3, 2023 | clinicaltrials |
| NCT01054625 | Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) | completed | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 4 | Aug 3, 2023 | clinicaltrials |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 306 | GenmabINDUSTRY | 6 | Aug 1, 2023 | clinicaltrials |
| NCT03438396 | A Trial of Tisotumab Vedotin in Cervical Cancer | completed | Phase 2 | 102 | Seagen Inc.INDUSTRY | 8 | Jul 25, 2023 | clinicaltrials |
| NCT00677924 | Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer(GEN206) | terminated | Phase 1 / Phase 2 | 9 | GenmabINDUSTRY | 1 | Jul 18, 2023 | clinicaltrials |
| NCT03637764 | Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 107 | SanofiINDUSTRY | 8 | Jul 10, 2023 | clinicaltrials |
| NCT02150967 | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma | terminated | Phase 2 | 143 | QED Therapeutics, a BridgeBio companyINDUSTRY | 11 | Jul 3, 2023 | clinicaltrials |
| NCT03772587 | A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis | completed | Phase 2 | 68 | Momenta Pharmaceuticals, Inc.INDUSTRY | 8 | Jun 27, 2023 | clinicaltrials |
| NCT03896295 | An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis | terminated | Phase 2 | 37 | Momenta Pharmaceuticals, Inc.INDUSTRY | 8 | Jun 27, 2023 | clinicaltrials |
| NCT03724071 | Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. | terminated | Phase 1 / Phase 2 | 51 | TransgeneINDUSTRY | 3 | Jun 23, 2023 | clinicaltrials |
| NCT01111461 | Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression | completed | Phase 2 | 133 | Eisai Inc.INDUSTRY | 8 | Jun 22, 2023 | clinicaltrials |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib(DASCERN) | completed | Phase 2 | 262 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 22, 2023 | clinicaltrials |
| NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON2) | completed | Phase 2 | 277 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT03911869 | An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis(POLARIS) | terminated | Phase 2 | 13 | PfizerINDUSTRY | 5 | May 31, 2023 | clinicaltrials |
| NCT05083247 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma(STEREOPAC) | recruiting | Phase 2 | 256 | Erasme University HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05865730 | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | unknown | Phase 2 | 122 | EverImmuneINDUSTRY | 2 | May 19, 2023 | clinicaltrials |
| NCT04616729 | DEPO-Trigger Trial: GnRH Agonist DEPOt TRIGGER for Final Oocyte Maturation(Depo-Trigger) | unknown | Phase 1 / Phase 2 | 30 | Universitair Ziekenhuis BrusselOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT03657043 | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | completed | Phase 2 | 98 | Seagen Inc.INDUSTRY | 6 | May 6, 2023 | clinicaltrials |
| NCT02823574 | Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 714) | completed | Phase 2 | 425 | Bristol-Myers SquibbINDUSTRY | 21 | May 3, 2023 | clinicaltrials |
| NCT03065621 | Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)(NeoRHEA) | completed | Phase 2 | 100 | Jules Bordet InstituteOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT01794520 | Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 117 | AbbVieINDUSTRY | 4 | Apr 10, 2023 | clinicaltrials |
| NCT04489940 | Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | terminated | Phase 2 | 11 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 6 | Apr 10, 2023 | clinicaltrials |
| NCT03785925 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer(PIVOT-10) | completed | Phase 2 | 192 | Nektar TherapeuticsINDUSTRY | 18 | Mar 28, 2023 | clinicaltrials |
| NCT01582776 | Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma | completed | Phase 1 / Phase 2 | 317 | The Lymphoma Academic Research OrganisationOTHER | 2 | Mar 17, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02598960 | An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread. | completed | Phase 1 / Phase 2 | 295 | Bristol-Myers SquibbINDUSTRY | 10 | Mar 6, 2023 | clinicaltrials |
| NCT02454972 | Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors | completed | Phase 2 | 345 | PharmaMarINDUSTRY | 9 | Mar 2, 2023 | clinicaltrials |
| NCT02807454 | A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma(FUSIONMM-003) | terminated | Phase 2 | 37 | CelgeneINDUSTRY | 9 | Feb 21, 2023 | clinicaltrials |
| NCT03386721 | Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors | terminated | Phase 2 | 256 | Hoffmann-La RocheINDUSTRY | 15 | Feb 21, 2023 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials